Live Breaking News & Updates on Clinical Research Center School

Stay updated with breaking news from Clinical research center school. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Safety data show Adbry well tolerated in treatment of moderate to severe atopic dermatitis

The results of pooled safety data for Adbry showed positive effects in the prolonged treatment of moderate to severe atopic dermatitis, according to a study. Adbry (tralokinumab, LEO Pharma) is the only FDA-approved biologic that specifically binds to and inhibits the interleukin (IL)-13 cytokine, one of the drivers of atopic dermatitis. ....

United States , United Kingdom , Ericl Simpson , Eric Simpson , Francesj Storrs , Medical Dermatology Professor , Clinical Research Center School , Oregon Health , Science University , British Journal ,